BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech showcases a strong financial foundation with approximately €16.7 billion in cash and cash equivalents as of the end of Q3 2025, highlighting the company's robust liquidity position. The promising efficacy results from its oncology pipeline, particularly with BNT326 showing favorable cORR and mPFS metrics compared to competitors, point to significant therapeutic potential and a competitive edge in the market. With multiple catalysts anticipated across its diverse pipeline, including upcoming interim Phase 3 data for additional treatments, the outlook for BioNTech remains positive as it progresses toward its goal of becoming a fully integrated oncology company.

The negative outlook on BioNTech's stock is primarily driven by the anticipated decline in COVID-19 vaccine revenues, expected to drop by 24% by FY26 and 5% sequentially thereafter as demand decreases post-pandemic. Additionally, challenges with manufacturing capacity for personalized therapeutics may hinder the company's ability to meet growth expectations, further complicating its oncology-focused pivot. Furthermore, the departure of key executives, including CEO Ugur Sahin and Chief Medical Officer Ozlem Tureci, raises concerns about future leadership stability and strategic direction, contributing to a notable drop in share value.